imprOving Adherence to Pulmonary artErial hyperteNsion Treatment With teLemedicIne and patieNt guidaNce

Launched by UNIVERSITY OF SAO PAULO GENERAL HOSPITAL · Feb 22, 2025

Keywords

ClinConnect Summary

The clinical trial titled "imprOving Adherence to Pulmonary artErial hyperteNsion Treatment With teLemedicIne and patieNt guidaNce" is exploring how remote monitoring can help patients with pulmonary arterial hypertension (PAH) stick to their treatment plans. PAH is a serious condition that affects blood flow in the lungs and can lead to heart problems. Even though there are treatments available, many patients struggle to follow their prescribed therapies, which can worsen their health. This study aims to see if using technology to monitor patients from home can improve their adherence to medication, overall health, and management of side effects.

To participate in this trial, individuals must be at least 18 years old and have a diagnosis of PAH. Participants should have been on stable oral medication for at least four weeks before joining and must have access to a phone or the internet for remote consultations. Those with severe cognitive issues, who cannot communicate through telemedicine, or are involved in other clinical trials may not be eligible. If you join, you'll have regular remote check-ins to ensure you're managing your treatment effectively, helping you stay on track with your health. This study is currently not recruiting participants yet, but it aims to make a significant difference in how PAH patients manage their condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adults aged ≥18 years diagnosed with pulmonary arterial hypertension (PAH) (Group 1 of the WHO classification).
• • Stable oral PAH therapy (including endothelin receptor antagonists, phosphodiesterase-5 inhibitors, or prostacyclin pathway agents) for at least four weeks prior to enrollment.
• • Ability to participate in remote teleconsultations (access to a phone or internet).
• • Signed informed consent agreeing to study participation.
• Exclusion Criteria:
• • Severe cognitive impairment or psychiatric disorders that could affect adherence or study participation.
• • Inability to communicate via phone or telemedicine due to technical or personal constraints.
• • Concurrent participation in another interventional clinical trial that could interfere with outcomes.
• • Life expectancy \<6 months due to any condition unrelated to PAH.
• • Pregnancy or breastfeeding.